Recent Advances in Cancer Immunology and Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 387
Special Issue Editors
Interests: oxidant stress; DNA damage and repair; microenvironment and tumorigenesis; nature products; inflammation and cancer
Special Issues, Collections and Topics in MDPI journals
2. School of Medicine, Tzu-Chi University, Hualien, Taiwan
Interests: acute lung injury; airway disease; pulmonary rehabilitation
Interests: integrated traditional Chinese and western medicine; acupuncture; pulmonary medicine; phytomedicine
Interests: cancer biology; Chinese herbal medicine; microRNA; biomarker; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has revolutionized the treatment of various cancers, but has also presented new challenges because of treatment-induced resistance mechanisms in tumors and changes to patients' innate and adaptive immune responses. Several studies have revealed that cancer cells communicate with the immune system dynamically. Dynamic interaction between the tumor and the immune system, and with the cancer-specific therapy, occurs with each immunotherapy. Understanding these interactions will lead to the development of novel combination therapies and innovative sequencing approaches. In this Special Issue, we welcome articles, reviews, and perspectives regarding clinical and translational cancer immunotherapy, including in vitro and in vivo studies about new immunotherapeutic approaches and tumor–immune cell interactions, acquired immunity resistance to immunotherapy, and immunotherapy biomarkers.
Dr. Chan-Yen Kuo
Dr. Chou-Chin Lan
Dr. Po-Chun Hsieh
Dr. Guan-Ting Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarker
- cancers
- cancer immunology
- immunotherapies
- immune cells
- immunotherapy resistance
- tumor immunology
